Mitochondria and Doxorubicin-Induced Cardiomyopathy: A Complex Interplay

Area of Science:

• Cardiology
• Oncology
• Mitochondrial Biology

Background:

• Cardiotoxicity is a significant side effect of doxorubicin (DOX) chemotherapy, leading to heart failure in up to 30% of patients.
• Heart failure is the primary non-cancer cause of death in patients treated with DOX.
• Despite identified mechanisms, clinical translation for DOX-induced cardiomyopathy (DCM) remains limited.

Purpose of the Study:

• To review the current understanding of DOX-induced cardiomyopathy (DCM).
• To highlight the critical role of mitochondria in DOX-induced cytotoxicity and cardiac dysfunction.
• To discuss current perspectives for preventing or treating DCM.

Main Methods:

• Literature review focusing on DOX-induced cardiomyopathy.
• Analysis of studies investigating mitochondrial function, dynamics, biogenesis, and autophagy in the context of DOX treatment.
• Synthesis of current knowledge on DCM pathophysiology, epidemiology, and therapeutic strategies.

Main Results:

• Mitochondria are increasingly recognized as key determinants of DOX-induced cardiotoxicity.
• DOX adversely affects mitochondrial function, dynamics, biogenesis, and autophagy, contributing to DCM.
• Understanding these mitochondrial mechanisms is crucial for developing effective interventions.

Conclusions:

• DOX-induced cardiomyopathy is a prevalent and serious condition for cancer survivors.
• Targeting mitochondrial pathways offers promising avenues for contrasting DCM development.
• Further research into mitochondrial protection strategies is essential for improving patient outcomes.